Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

FDA approval announcement for ofatumumab
Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study.
Tcelna® (imilecleucel-T)
Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes.
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Current and future disease-modifying therapies in multiple sclerosis.
Alemtuzumab
Withdrawal of the marketing authorization in the European Union
Altered serum content of brain-derived neurotrophic factor isoforms in multiple sclerosis.
Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis.
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration.
Efficacy and safety study of RPC1063 in relapsing multiple sclerosis patients
No Differences Observed among Multiple Clinical S1P1 Receptor Agonists (Functional Antagonists) in S1P1 Receptor Down-regulation and Degradation.
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.
Impact of cladribine on soluble adhesion molecules in multiple sclerosis.
Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis.
Interferon Beta-1b may reverse axonal dysfunction in multiple sclerosis.
Lithium Controls Central Nervous System Autoimmunity through Modulation of IFN-γ Signaling.
Interferon β for secondary progressive multiple sclerosis: a systematic review.
Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™).
Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes.
Placebo-controlled trial of oral laquinimod for multiple sclerosis.
Inflammation-induced fatigue: Exploring neurobiological mechanisms and potential treatments
Control of oxidative stress and inflammation in sickle cell disease with the Nrf2 activator dimethyl fumarate.

Pages